Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Your RPS

Royal Pharmaceutical Society releases new pharmacovigilance guidance

Woman reading a patient information leaflet, where the 'black triangle' can be found

Source: Jochen Tack / Alamy Stock Photo

Pharmacists, other healthcare professionals and patients should report any suspected adverse reaction for medicines with a black triangle

The Royal Pharmaceutical Society (RPS) has launched new guidance on the EU-wide scheme for the additional monitoring of medicines, commonly known in the UK as the ‘black triangle’ scheme.

In collaboration with the Association of the British Pharmaceutical Industry’s (ABPI) Pharmacovigilance Expert Network (PEN), the RPS has produced a quick reference guide and an ‘Advice for pharmacists’ document highlighting the importance of the black triangle and explaining the ways in which healthcare professionals can contribute to medicines’ safety by being vigilant and reporting any adverse reactions to black triangle medicines.

In the EU, a black triangle is usually assigned to a medicine for five years following initial authorisation. It can then be reinstated at any later stage in a medicine’s life cycle if there are safety concerns that require monitoring. The black triangle can be found next to the name of relevant medicines on the summary of product characteristics, patient information leaflet, in the BNF or on advertising and educational materials for healthcare professionals and patients.

Pharmacists, other healthcare professionals and patients are encouraged to report any suspected adverse reaction for medicines with a black triangle. Reports can be submitted via the Yellow Card scheme and/or directly to the marketing authorisation holder.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201792

Readers' comments (1)

  • The importance of pharmacovigilance cannot be emphasised enough. Healthcare professionals have a crucial part to play in the reporting of adverse events, which is one element of pharmacovigilance. For those of you who are interested in the definition of 'Pharmacovigilance', please check out the link below on the WHO website. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
    One other fact to bear in mind is that there is also a Yellow card app available from the Apple app store or the Google Play store. This app can be used for reporting adverse events and it has other very useful features too. Below is a link to to the Yellow card scheme page on the MHRA website where you can find further information on the app.
    https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Woman reading a patient information leaflet, where the 'black triangle' can be found

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.